Category: Uncategorised

• OneChain’s CD22 CAR technology and NanoCell’s non-viral, DNA-based in vivo CAR-T platform will be utilized to develop innovative treatment options.

PA, USA Wayne and Barcelona, Spain,  – May 16 2024, —  OneChain Immunotherapeutics S.L. (OneChain) and NanoCell Therapeutics Inc. (NanoCell), announced today a strategic collaboration to develop a novel in vivo CAR-T therapy targeting B-cell lymphomas. This partnership combines OneChain’s advanced CD22 CAR technology with NanoCell’s innovative in vivo CAR-T technology platform, opening a new course for treatment in this disease area with persisting unmet need.

NanoCell’s non-viral, DNA-based CAR-T technology platform has demonstrated compelling results in pre-clinical proof of concept studies, durable CAR-T expression and robust tumor control. This new approach offers a viable alternative to conventional viral methods, potentially establishing a new standard in the field.

OneChain’s proprietary CD22 CAR molecule was developed and optimized by Professor Pablo Menendez, founder of OneChain and Professor at the Josep Carreras Institute for Leukemia. Preclinical validation of this CD22 CAR has been published in multiple peer-reviewed academic journals¹.

“Partnering with NanoCell allows us to integrate our CD22 CAR with their innovative in vivo CAR-T technology, aiming to enhance treatment options for B-cell lymphoma”, said Stefanos Theoharis, CEO of OneChain Immunotherapeutics.

“We look forward to collaborating with OneChain Immunotherapeutics, and potentially offering innovative treatments beyond traditional CD19 therapies for patients with B-cell malignancies”, added Maurts Geerlings, CEO of NanoCell Therapeutics.

To learn more about our work and stay updated about our latest developments, please visit our websites at https://www.onechaintx.com/ and http://www.nanocelltx.com.

About OneChain Immunotherapeutics

OneChain Immunotherapeutics was founded in June 2020 by the Josep Carreras Leukaemia Research Institute, ICREA, and Dr. Pablo Menéndez. It is currently supported by a group of partners including the Josep Carreras Leukemia Foundation, venture capital entities Invivo Partners, Nara Capital, and Clave Capital, and the Center for Technological Development and Innovation (CDTI). The company, with headquarters at the Barcelona Science Park, focuses on developing treatments based on immunotherapy for malignant neoplasms. More information: https://www.onechaintx.com/

About NanoCell Therapeutics, Inc.

NanoCell Therapeutics is a privately held, transatlantic biotechnology company with locations in Wayne, Pennsylvania, and Utrecht, the Netherlands. We are dedicated to pioneering transformative in-vivo cell engineering through our non-viral, DNA-based gene therapy platform, primarily targeting oncology and autoimmune diseases. NanoCell’s advanced technology platform aims to evolve and enhance traditional adoptive cell therapy methods into advanced in-vivo treatments. Our objective is to streamline the overall treatment process, bolstering patient access, potential clinical benefits, and cost-effective manufacturing.

OneChain Immunotherapeutics S.L. | Communication and press office
Telephone | +34 913766458
E: press@scienseed.com 

NanoCell Therapeutics Inc. | Investor Relations & Media
A. Lindman, MBA | T: +31 (0) 70 3643095
E: contact@nanocelltx.com

¹Velasco- Hernandez T, Zanetti SR, Roca- Ho H, et al. Efficient elimination of primary B- ALL cells in vitro and in vivo using a novel 4- 1BB- based CAR targeting a membrane-distal CD22 epitope. Journal for ImmunoTherapy of Cancer 2020;8:e000896. doi: 10.1136/jitc-2020-000896.

Wayne, PA – March 19, 2024 — NanoCell Therapeutics, Inc. (“NanoCell”), a company developing in-vivo cell engineering solutions based on its proprietary non-viral, DNA-based gene therapy platform, today announced the appointment of Charles F. Albright, Ph.D., to its Scientific Advisory Board.

“We’re honored to welcome Charles, a globally recognized scientist with a distinguished career in biotechnology and pharmaceuticals, to NanoCell’s Scientific Advisory Board,” said Maurits Geerlings, NanoCell’s Chief Executive Officer. “Charles is contributing to the scientific diversity of our board with his deep expertise in gene editing, gene delivery and drug discovery. He will bring significant value as we are expanding our pipeline in oncology and autoimmune diseases through our innovative in-vivo cell engineering platform.”

Dr. Albright is the Chief Scientific Officer at Affinia Therapeutics, leading the creation of innovative AAV vectors for gene therapy. Previously, as Executive Vice President and Chief Scientific Officer at Editas Medicine, he played a pivotal role in pioneering CRISPR gene editing therapies, following his position as Vice President at Bristol-Myers Squibb Company, focusing on Genetically Defined Diseases and Genomics. Dr. Albright’s contributions include advancing genetic disease and cancer treatments, notably his work on the first IND for in vivo CRISPR/Cas9 editing.

“NanoCell’s in-vivo gene therapy platform is a versatile non-viral, DNA based technology targeting cancer and autoimmune diseases by enabling direct, in-body cell engineering,” said Dr. Charles. “I am pleased to join the Company at this exciting stage as a member of the Scientific Advisory Board and help advance this innovative technology to make a difference in the lives of people impacted by cancer and other serious diseases.”

 

About NanoCell Therapeutics, Inc.

NanoCell Therapeutics is a privately held, transatlantic biotechnology company with locations in Wayne, Pennsylvania, and Utrecht, the Netherlands. We are dedicated to pioneering transformative in-vivo cell engineering through our non-viral, DNA-based gene therapy platform, primarily targeting oncology and autoimmune diseases. NanoCell’s advanced technology platform aims to evolve and enhance traditional adoptive cell therapy methods into advanced in-vivo treatments. Our objective is to streamline the overall treatment process, bolstering patient access, potential clinical benefits, and cost-effective manufacturing. For more information, visit: http://www.nanocelltx.com.

Investor Relations & Media
A. Lindman, MBA
+31 (0) 70 3643095
contact@nanocelltx.com

King of Prussia, PA – September 26, 2023 – NanoCell Therapeutics, Inc. (“NanoCell”) is pleased to announce the appointment of Dr. Jacek Lubelski as its new Chief Technology Officer (CTO), effective immediately. Dr. Lubelski brings over a decade of experience in the biopharmaceutical industry and is recognized for his pioneering work in gene therapy technologies, particularly in recombinant adeno-associated virus (rAAV) therapeutics.

Prior to joining NanoCell, Dr. Lubelski served as the VP of Pharmaceutical Development at UniQure NV (NASDAQ: QURE). During his tenure, he contributed to the development of multiple rAAV-based advanced therapy medicinal products (ATMPs) to address complex diseases, such as Haemophilia B, and Huntington disease. Dr. Lubelski was involved in obtaining market authorization for Glybera, a groundbreaking gene therapy medicine for lipoprotein lipase (LPL) deficiency and most recently Hemgenix.

His leadership extended to overseeing vector development, process development, analytical methods, pre-clinical studies, and CMC activities, resulting in significant advancements in viral vector manufacturing platforms. As CTO, Dr. Lubelski will lead strategic technology initiatives, drive innovation in gene and cell therapy, and reinforce NanoCell Therapeutics’ position as a pioneering force in the biotech sector.

Maurits W. Geerlings, President and CEO of NanoCell Therapeutics, remarked, “Under Jacek’s guidance, NanoCell Therapeutics is poised to continue advancing the frontiers of gene and cell therapy. His expertise and dedication will be instrumental in our pursuit of cutting-edge solutions for patients worldwide.”

Dr. Lubelski holds a Ph.D. in Molecular Microbiology from the University of Groningen and a master’s degree in biotechnology from Maria Curie-Sklodowska University in Lublin, Poland. He is currently pursuing eMBA studies at the Rotterdam School of Management, Erasmus University in Rotterdam, the Netherlands.

Dr. Lubelski expressed his enthusiasm for his new role, stating, “I’m excited to step into the position of Chief Technology Officer at NanoCell Therapeutics. We have the potential to drive transformative advancements in gene and cell therapy, and I look forward to leading our outstanding scientific team to achieve these goals.”

 

About NanoCell Therapeutics, Inc.

NanoCell Therapeutics is a privately-held biotechnology company with offices in King of Prussia, Pennsylvania, and Utrecht, the Netherlands. Our mission is to revolutionize in-vivo cell engineering through our groundbreaking non-viral, DNA-based gene therapy platform, primarily focusing on oncology and autoimmune diseases. At NanoCell, we’re driving innovation by transforming traditional adoptive cell therapy methods into advanced in-vivo treatments. Our ultimate goal is to simplify the treatment process, increasing patient accessibility, potential clinical benefits, and cost-effective manufacturing. We work both autonomously and in collaboration with partners to make substantial advancements in our targeted disease areas. For more information, please visit our website at http://www.nanocelltx.com.

Investor & Media Contact:
A. Lindman, MBA
+31 (0) 70 3643095
nanocelltx@koraliscorporate.com

King of Prussia, PA – August 3, 2023 – NanoCell Therapeutics, Inc. (“NanoCell”) today announced the appointment of Dr. Florence G.C. Salmon to its Scientific Advisory Board (“SAB”). Dr. Florence G.C. Salmon joins NanoCell Therapeutics as a member of its SAB and as an Executive Advisor, leveraging her extensive expertise in regulatory affairs and complex biologics manufacturing.

“We eagerly anticipate collaborating with Dr. Florence Salmon, a renowned expert in genetically modified T cells for cancer immunotherapy,” remarked Maurits W. Geerlings, President and CEO of NanoCell Therapeutics. “With Dr. Salmon’s profound understanding of regulatory affairs and complex biologics manufacturing, we’re poised to unlock the full potential of our in vivo gene therapy platform and its associated drug candidates,” added Dr. Geerlings.

Joining NanoCell’s SAB, Dr. Salmon will work alongside esteemed members like Dr. Molly Stevens of Imperial College London, Dr. Dan Peer from Tel Aviv University, Dr. Gianpietro Dotti from the University of North Carolina, Dr. Perry Hackett at the University of Minnesota, and Dr. Marlene Haffner, formerly the Director of the US Food and Drug Administration’s Office of Orphan Drug Products Development. The SAB acts as a strategic guide for NanoCell in its ongoing efforts to develop in vivo gene therapies for cancer and autoimmune diseases.

As a distinguished drug development and regulatory professional, Dr. Salmon possesses unique expertise in spearheading the development and approval of global Cell and Gene Therapies such as Glybera, Kymriah, Zolgensma, and Luxturna. Her vast experience spans non-clinical development, safety, and manufacturing of viral vectors and human adoptive cell therapies. Moreover, her influential role since the early 2000s as a member of EFPIA and BIO working groups on ATMPs and as chair of the EFPIA working group on ATMPs manufacturing and GMP has endowed her with an expansive industry and regulatory network.

On her appointment, Dr. Salmon expressed, “The assembly of thought leaders on NanoCell’s SAB represents a premier team of global authorities in cancer and nanomedicine. I’m honored to collaborate with this caliber of experts and eagerly anticipate contributing to NanoCell’s innovative approach to in vivo gene therapy for the betterment of patients.”

  

About NanoCell Therapeutics, Inc.

NanoCell Therapeutics is a privately-held biotechnology company with offices in King of Prussia, Pennsylvania, and Utrecht, the Netherlands. Our mission is to revolutionize in-vivo cell engineering through our groundbreaking non-viral, DNA-based gene therapy platform, primarily focusing on oncology and autoimmune diseases. At NanoCell, we’re driving innovation by transforming traditional adoptive cell therapy methods into advanced in-vivo treatments. Our ultimate goal is to simplify the treatment process, increasing patient accessibility, potential clinical benefits, and cost-effective manufacturing. We work both autonomously and in collaboration with partners to make substantial advancements in our targeted disease areas. For more information, please visit our website at http://www.nanocelltx.com.

Investor & Media Contact:
A. Lindman, MBA
+31 (0) 70 3643095
nanocelltx@koraliscorporate.com

King of Prussia, PA and Utrecht, The Netherlands – January 4, 2023 – NanoCell Therapeutics, Inc. (“NanoCell”) today announced that its syndicate with Utrecht University (UU), Imperial College London (ICL), Karolinska Institutet (KI) and SINTEF was awarded 3 million Euro for the development of NanoCell’s first-in-class technology platform to enable in vivo cell gene therapy to treat a broad range of diseases, including cancer and genetic disorders.

The multinational consortium, known as NANO-ENGINE, combines NanoCell’s expertise in non-viral gene transfer technologies and in vivo cell engineering with UU’s Pharmaceutical Sciences division’s proficiency in nanomedicine chemistry. ICL has pioneered a groundbreaking single particle analysis method to be implemented at KI, providing the consortium with unparalleled insights into drug product characterization. Additionally, SINTEF contributes essential knowledge in bulk analysis of the drug product and plays a vital role in establishing regulatory standards for nucleic acid therapeutics.

“We are honored to have been awarded this highly competitive grant and are looking forward to work with our internationally esteemed consortium partners” said Maurits Geerlings, President and CEO of NanoCell. “The EIC Pathfinder Challenges program recognizes the potential of our non-viral, DNA- based in vivo gene therapy platform overcoming the most critical limitations of adoptive cell therapies. We believe that the NANO-ENGINE program will play a pivotal role in advancing the development of groundbreaking therapies for life-threatening diseases. Our commitment is to ensure these innovative treatments become not only more affordable and scalable but also safer and more effective. Ultimately, our mission is to make these transformative therapies readily available to patients worldwide,” added Dr. Geerlings.

While NANO-ENGINE’s focus is on developing in vivo gene therapy for B cell malignancies, the program helps accelerate further development of the platform across other disease areas, such as myeloid and T cell malignancies, solid tumors, autoimmune/inflammatory diseases, genetic disorders and beyond. For more information, visit https://nano-engine.eu.

 

About NanoCell

NanoCell Therapeutics is a privately-held biotechnology company with offices in King of Prussia, Pennsylvania, and Utrecht, the Netherlands. Our mission is to revolutionize in-vivo cell engineering through our groundbreaking non-viral, DNA-based gene therapy platform, primarily focusing on oncology and autoimmune diseases. At NanoCell, we’re driving innovation by transforming traditional adoptive cell therapy methods into advanced in-vivo treatments. Our ultimate goal is to simplify the treatment process, increasing patient accessibility, potential clinical benefits, and cost-effective manufacturing. We work both autonomously and in collaboration with partners to make substantial advancements in our targeted disease areas. For more information, visit http://www.nanocelltx.com).

Investor & Media Contact:
A. Lindman, MBA
+31 (0) 70 3643095
nanocelltx@koraliscorporate.com